Pre-made Flanvotumab benchmark antibody ( Whole mAb, anti-TYRP1 therapeutic antibody, Anti-TRP/CAS2/CATB/GP75/OCA3/TRP1/TYRP/b-PROTEIN Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Flanvotumab biosimilar, Whole mAb, Anti-TYRP1 Antibody: Anti-TRP/CAS2/CATB/GP75/OCA3/TRP1/TYRP/b-PROTEIN therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma. It targets TYRP1.
| Products Name (INN Index) | Pre-Made Flanvotumab biosimilar, Whole mAb, Anti-TYRP1 Antibody: Anti-TRP/CAS2/CATB/GP75/OCA3/TRP1/TYRP/b-PROTEIN therapeutic antibody |
|---|---|
| INN Name | Flanvotumab |
| Target | TYRP1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2011 |
| Year Recommended | 2012 |
| Companies | ImClone Systems,Eli Lilly |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Malignant melanoma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TYRP1 |
| Package |
